Fundraising Fox
Cure51
Founded 2021 · 61 employees on LinkedIn · 4 known investors
Find your way into Cure51
Sign up to see every warm intro you have to Cure51
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cure51 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform. It works with cancer centers and clinical partners as part of the Rosalind Study to advance cancer research.
Founders & leadership
Cure51 was founded in 2021 by Paloma Cejas and Rémy Nicolle.
Investors · 4
How we know: funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Kima Ventures's portfolio page · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountseed roundMar 2024 · 4 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Cure51 went on to found or lead other companies.
In the news
Frequently asked questions
- What does Cure51 do?
- Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform. It works with cancer centers and clinical partners as part of the Rosalind Study to advance cancer research.
- Who founded Cure51?
- Cure51 was founded by Paloma Cejas, Rémy Nicolle in 2021.
- Who are Cure51's investors?
- Cure51's investors include Hitachi Ventures, Kima Ventures, LifeX Ventures, Sofinnova Partners.